NEWT NewtekOne, Inc. Insider Trading

CEO Barry Sloane buys 5,000 NEWT shares at $14.20; 4 of 5 prior same-ticker buys were well-timed at 90d, cluster pattern evident

Barry Sloane, President, Chairman & CEO, purchased 5,000 shares at $14.20 on 2026-06-15, bringing his holdings to 1,181,914 shares post-transaction. This open-market buy occurs within a cluster context: 2 other insiders bought within the past 14 days, suggesting coordinated management confidence. The timing signal is meaningful: at this same ticker (NEWT), Sloane's prior buy on 2026-01-14 declined 8.6% over 30 days and 9.7% over 90 days, but 4 of his 5 prior NEWT trades were well-timed at the 90-day mark, with the November 2025 buys each posting 30-day returns of +10.2% to +11.0% and 90-day returns of +31.4% to +32.4%. Current stock price is $14.30 (near the transaction price), up 12.8% over 30 days and 19.4% over 90 days, consistent with the strong momentum pattern Sloane captured in his November cluster. The company trades at a P/E of 6.38 with $38.2M quarterly revenue and $13.4M net income, presenting modest valuation metrics relative to market cap of $412.7M.

Barry Sloane (CEO) purchases 11,000 shares at $14.21 avg; stock up 12.8% in 30 days, 19.4% in 90 days

CEO Barry Sloane executed 3 separate purchases totaling 11,000 shares for $156,260.00 at a blended average price of $14.21, expanding his holdings to 1,176,914 shares. The stock has appreciated 12.8% over the prior 30 days and 19.4% over the prior 90 days, trading at $14.30 against a 52-week range of $9.59–$14.91. His same-ticker purchase history at NEWT shows 4 of 5 prior buys were followed by positive 90-day returns, with 3 consecutive purchases on 2025-11-03 each yielding 90-day gains between +31.4% and +32.4%, suggesting a pattern of well-timed entry points at this specific ticker. The company trades at a P/E of 6.38 on revenue of $38,166,000.00 and net income of $13,401,000.00 in the latest quarter.

Director Craig Jeffry Brunet buys 1,000 shares of NEWT at $12.70; holdings rise to 7,185 shares (+16.2%)

Craig Jeffry Brunet, a director of NewtekOne, purchased 1,000 shares at $12.70 on 2026-06-03, increasing his holdings by 16.2% from 6,185 to 7,185 shares. The transaction occurs at a price -15.2% from the 52-week high of $14.91, with the company trading at a P/E of 5.65 and reporting $38.2M in latest-quarter revenue and $13.4M in net income. Reviewing his prior trades at NEWT, Brunet's timing record is mixed: 2 of 4 prior buys showed positive 90-day returns (+1.0%, +9.9% and +0.6%, +6.5%), while 2 showed negative 90-day returns (-18.0%, -16.2% and +0.4%, -3.8%). His cross-ticker track record shows 4 prior buys with an average 90-day return of -0.9% and a 50% win rate, indicating consistent participation but without a strong pattern of favorable outcomes across holdings.

Director Zink Gregory L purchases 1,000 shares of NEWT in open-market buy, 16th open-market purchase in 36 months with mixed prior timing outcomes.

Director Zink Gregory L added to his stake with an open-market purchase of 1,000 shares, continuing a consistent pattern of accumulation—this is his 16th open-market purchase over the past three years with no open-market sales. The stock is trading modestly below its 52-week high, having climbed sharply over the prior month from depressed levels. His prior five trades at NEWT show mixed timing results: four of five purchases saw the stock rise in the subsequent month, though the 90-day picture was more split, with three trades followed by gains and two followed by declines. NewtekOne remains a profitable company with a low valuation multiple relative to earnings and solid recent quarterly results, providing a financial backdrop to the accumulation. The persistence of open-market buying—especially given the mixed but not poor near-term track record—underscores steady conviction in the business at current levels.

NewtekOne director Richard J. Salute makes open-market purchase of 1,000 shares, extending a consistent buying pattern with no prior sales on record.

Richard J. Salute, a director at NewtekOne, made a modest open-market purchase that adds to an extensive history of buying — he has made 14 prior open-market purchases with zero open-market sales on record. The stock is trading well off its fifty-two-week lows and has rallied strongly over the past month, placing Salute's purchase near the higher end of its recent range but still meaningfully below the year's peak. NewtekOne is a profitable company trading at what appears to be a low valuation multiple relative to its earnings, which provides some fundamental backdrop for the purchase. Salute's prior buys in this stock have shown a conflicting pattern across time horizons: every one of the five tracked prior purchases was followed by a stock gain in the near term, but outcomes over the longer ninety-day window were more mixed, with roughly half seeing positive and half seeing negative results. This is a routine-sized addition to his position, and while Salute's near-term track record has been uniformly positive in prior instances, the modest scale and absence of any cluster of insider activity make this a relatively low-urgency signal on its own.

CLO Michael Schwartz buys 2,247 shares of NEWT at $13.91; 3 other insiders buy within 14 days

Michael Schwartz, Chief Legal Officer of NewtekOne, purchased 2,247 shares at $13.91 on 2026-01-14, increasing his holdings to 49,713 shares. This transaction is part of a cluster pattern, with 3 other insiders also buying within the past 14 days. The stock has appreciated 21.2% over the past 30 days and 39.7% over the past 90 days, currently trading at $14.64, near its 52-week high. NewtekOne's fundamentals show a P/E of 7.14 with recent quarterly net income of $17,901,000.00 against revenue of $38,166,000.00, suggesting operational profitability. The multiple insider purchases in proximity warrant investor attention as they reflect leadership appetite for share ownership at current valuations.

SVP HR buys 1,258 shares of NEWT at $13.91; cluster of 3 other insiders buying within 14 days; stock up 39.7% in 90 days.

Razon-Feingold Halli, SVP of Human Resources & CAO, purchased 1,258 shares at $13.91, increasing holdings to 22,915 shares. The transaction occurred at a price within 5% of the current market price of $14.64, suggesting near-market-level entry. Notably, this purchase is part of a broader cluster pattern: 3 other insiders also bought within the past 14 days, indicating coordinated or simultaneous accumulation across the management team. The stock has appreciated sharply—up 39.7% over 90 days and currently at its 52-week high of $14.64—alongside solid fundamentals: the company reported $38.2M in revenue and $17.9M in net income, yielding a P/E of 7.14 and market cap of $422.9M. The convergence of multiple insiders purchasing during strong price momentum warrants investor attention to the underlying business drivers and whether this cluster reflects genuine confidence or is incidental to scheduled equity programs.

CEO Sloane Barry buys 3,595 shares of NEWT at $13.91 as 3 other insiders also buy within 14 days; stock up 21.2% in 30 days, 39.7% in 90 days.

Sloane Barry, President, Chairman & CEO of NewtekOne, Inc., purchased 3,595 shares at $13.91 on 2026-01-14 for $50,006.45, increasing his holdings to 1,194,180 shares. This transaction occurs within a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated confidence at the management level. The timing aligns with strong recent price momentum—NEWT has risen 21.2% over the past 30 days and 39.7% over 90 days, currently trading at $14.64 near its 52-week high of $14.64. Fundamentally, the company shows solid metrics with net income of $17,901,000.00 against revenue of $38,166,000.00 (latest quarter) and a P/E ratio of 7.14. Barry's cross-ticker buy track record demonstrates an 80.00% 90-day win rate with an average 90-day return of +8.7%, though his same-ticker history at NEWT (5 prior buys all on 2025-11-03) shows recent 30-day returns of +10.2% to +11.3%, with 90-day outcomes not yet measurable. The cluster buy pattern combined with strong momentum and management confidence warrants investor attention to whether this reflects conviction in upcoming catalysts or recognition of undervaluation relative to fundamentals.

CFO Frank M DeMaria buys 1,556 shares of NEWT at $13.91; 3 other insiders bought within 14 days (cluster buy)

DeMaria's purchase of 1,556 shares at $13.91 on 2026-01-14 represents a +4.6% increase in his holdings to 35,220 shares. The transaction occurs during a period of strong price appreciation: NEWT has risen 21.2% over the past 30 days and 39.7% over 90 days, currently trading at $14.64, the 52-week high. Most notably, this buy is accompanied by a cluster pattern—3 other insiders also purchased shares within the past 14 days—which often signals coordinated confidence or reaction to shared information. DeMaria's own cross-ticker track record shows 100% win rate on his prior buys at the 90-day mark, though he has only 1 prior transaction at NEWT (which returned +7.8% over 90 days). The stock trades at a P/E of 7.14 with strong fundamentals: $38.2M in latest quarterly revenue and $17.9M in net income.

Director Zink Gregory L buys 500 NEWT shares at $12.06; cluster pattern with 2 other insiders buying within 14 days.

Director Zink Gregory L purchased 500 shares at $12.06 on 2025-12-15, increasing holdings by 1.3% to 37,707 shares. The purchase occurs as part of a cluster pattern, with 2 other insiders also buying within the past 14 days, suggesting coordinated interest in the stock at current levels. At the time of this purchase, the stock was trading -17.0% from its 52-week high and had appreciated +17.6% over the preceding 30 days, placing the transaction near a relative peak within recent momentum cycles. Examining the director's prior 5 trades at NEWT shows mixed timing outcomes: 2 of 4 completed trades (50%) delivered positive 90-day returns, while 2 experienced declines, indicating modest predictive value in his ticker-specific activity; his cross-ticker track record shows a 38.46% win rate over 90 days, further suggesting limited historical success at identifying optimal entry points.